Ceribell files complaints against Natus Medical

By Ahmed Jameison • Tuesday, July 08 15:29 • Permanent Link

Ceribell, Inc. (NASDAQ: CBLL) has recently filed complaints against Natus Medical Incorporated, alleging patent infringement and unfair competition. The complaints were filed with both the U.S. International Trade Commission (USITC) and the U.S. District Court in Delaware. Ceribell has requested that the USITC investigate its claims and issue an exclusion order to bar the importation of any infringing Natus products into the United States.

Ceribell believes that Natus is infringing six of its patents related to important features of its EEG headband and electrode design. Jane Chao, Ph.D., co-founder and CEO of Ceribell, emphasized the significant investments the company has made in point-of-care EEG technology and its commitment to fair competition.

This move comes as Ceribell seeks to protect its intellectual property and innovations in the healthcare community, with a focus on delivering leading-edge products to healthcare professionals and their patients. Following these announcements, the company's shares moved -0.99%, and are now trading at a price of $17.03. For the full picture, make sure to review Ceribell's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.